Pengaruh suplementasi Astaxamin terhadap kadar Malondialdehida plasma dan skor National Institute of health Stroke Scale (NU-ISS) pada penderila stroke iskemik. Mengetahui efek pcmberian suplementasi Astaxantin selama tujuh hari terhadap kadar malondialdehida plasma dan skor NIHSS pada penderita stroke iskemik Penelitian ini merupakan uji klinis pamlel, acak, tcrsamar ganda antara kelompok yang znendapat suplementasi astaxantin (P) dengan kelompok yang mendapat plasebo (K), Sebanyak 24 orang pasien stroke iskemik akut dengan onset < 48 jam di RSUPNCM Jakarta memenuhi kriteria dan diikutkan dalam penelitian, dilakukan alokasi random menggunakan randomini blok untuk menemukan kelompok perlakuan dan kontrol. Kelompok perlakuan mendapatkan suplementasi Astaxantin 2 x 8mg/had peroml selama tujuh hari, sementara kelompok kontrol mendapat plascbo. Data yang dikumpulkan meliputi data demografi (usia, jenis kelamin, tingkat pcndidikan, tingkat penghasilan), onset serangan, faktor risiko, IMT, analisis asupan zat gizi, kadar malondialdehida plasma, serta skor NIHSS. Analisis dam menggunakan uji 1 tidak berpasangan atau uji Man Whitney dengan batas kemaknaan p < 0,05. Rerata usia subjek penelitian ini adalah 56,0l=i:6,44 tahun. Sebagian besar subyek berjenis kelamin laki-laki, berpendidikan rendah dan tingkat penghasilan di bawah garis kemiskinan. Faktor risiko stroke yang paling banyak dimiliki subyek penelitian adalah hipertensi, diikuti kebiasaan merokok, dislipidemia, obesitas, diabetes mellitus, dan penyakit jantung. Selama perlakuan, asupan energi dan protein subyek penelitian tergolong cukup, asupan lemak tergolong lebih, asupan vitamin C tergolong cukup, sedangkan asupan vitamin E dan beuz kanaten tagolong kurang pada kedua kelompok. Terdapat penurunan kadar MDA plasma dan skor NIHSS pada kedua kelompok selama perlakuan. Rerata penurunan kadar MDA plasma pada kelompok perlakuan adalah -0,3l6i0,l8 normal dan secara bermakna lebih bcsar dibandingkan kelompok kontrol yaitu -0,1241 0,I08 nmol/mL (p<0,05). Penurunan skor NIHSS pada kelompok perlakuan sebesar -5,67=|=l,37 secara bermakna lebih besar dibandingkan kelompok kontrol yaitu ~3,‘25:&0,87 (p <0,0S). Suplcmentasi aataxantin sebanyak 2 x 8 mg solama 7 hari sccara bermakna dapal menurunkan kadar MDA plasma dan skor NIHSS penderila stroke iskemik. Astaxantin, antioksidan, malondialdehida plasma, skor Nll-ISS, stroke iskemik.

---

Bilects of Astaxantin suplcmentation on malondialdehyde plasma level and National Institute of health Stroke Scale (NIHSS) score of ischemic stroke patients To investigate the effects of Astaxantin supplementation during seven days on Malondialdchida plasma level and NIHSS score of ischemic strokc patients. This is a parallel randomized double-blind clinical study between interventional group which has astaxantin supplementation (P) and control group which has placebo (K). Twenty-four acute ischemic stroke patients with onset < 48 hours in RSUPNCM Jakarta had fullilled the criteria and recruited in the research. Subjects were random allocated by block randomimtion into intervention and control group. Intervention group treated by Astaxnntin 2 x Sing,/day supplementation orally during 7 days, while control group treated by placebo. Data collection includes demographic characteristic (nge, sex, educational level, income level), stroke onset, risk factors, body mass index (BMI), daily nutrient analysis, malondialdchida plasma level, and Nil-lSS score. Statistical analysis is using unpaired t test or Mann Whitney test with significant level at p < 0,05. The mean age of subjects were 56,0li6,44 years old. Majoritics of suljects were male, low educational level and below poverty level income. The most liequent stroke risk factors in subjects were hypertension, followed by smoking habit. dyslipidemia, obesity, diabetes mellitus, and heart diseases. During intervention, energy and proteins intake were adequate, fat intake tends to be excess, vitamin C intake was adequate, whiie vitamin E and beta kamten tends to be low in both two groups. 'lhere was decreasing in MDA plasma level and NI]-ISS score in both two groups during intervention. The mean decreasing of MDA plasma in interventional group was -0,3lG.k0,l8 nmol/mL which significantly greater than control group -0,1242 0,108 nmol/mL (p<0,05). The mean decreasing ofNlHSS score in interventional group was -5,67=el,37 which significantly greater than control group -3,25i0,87 (p <0,05). Astaxantin supplementation 2 x 8 mg during 'l days is signiiicant on decreasing MDA plasma level and NH-ISS score in ischemic stroke patients. Astaxantin, antioxidant, rnalondialdehicla plasma, NIHSS score, ischemic stroke.